Peritumoral microenvironment affects cancer development and chemoresistance, and visceral adipose tissue may play a critical role. We aimed to identify depotspecific adipose characteristics associated with carcinogenesis and resistance to neoadjuvant therapy in esophageal adenocarcinoma (EAC). We analyzed: (i) the peritumoral adipose tissue of rats following the induction of esophageal carcinogenesis; (ii) the peritumoral and distal (omental) adipose tissue of patients affected by EAC; (iii) adipose-derived stem cells (ADSC) isolated from healthy patients and treated with conditioned medium (CM), collected from tumoral and adipose tissue of patients with EAC. In peritumoral adipose tissue of rats, CD34, CD31 and vascular endothelial growth factor (VEGF) expression increased progressively during EAC development. In patients with EAC, expression of CD34, CD45, CD90 and nucleostemin (NSTM) was higher in peritumoral than in distal adipose tissue and decreased in the presence of neoadjuvant therapy. Moreover, expression of NSTM, octamer-binding transcription factor 4 (OCT-4) and VEGF was higher in peritumoral (but not in distal) adipose tissue of chemoresistant patients. In ADSC, treatment with peritumoral adipose tissue CM increased the adipogenic potential and the expression of CD34, CD90, NSTM and OCT-4. These effects were similar to those induced by cancer-derived CM, but were not observed in ADSC treated with distal adipose tissue CM and were partially reduced by a leptin antagonist. Last, ADSC treated with peritumoral CM of chemoresistant patients displayed increased expression of NSTM, OCT-4, leptin, leptin receptor, alpha-smooth muscle actin (a-SMA), CD34 and VEGF. These results suggest that peritumoral adipose tissue may promote, by paracrine signaling, the expression of depot-specific factors associated with therapeutic resistance.
A dipose tissue distribution can affect overall and diseasefree survival in gastric cancer (1) and fat-mass loss after neoadjuvant therapy seems to be associated with progressionfree survival in pancreatic cancer.
(2) Moreover, an excess of visceral adipose tissue is related to a poorer response to neoadjuvant therapy in breast cancer.
(3) It has been hypothesized that the pathophysiology of adipose tissue might influence the clinical outcome of patients, but no clear consensus exists on the pathways directly involved in this process.
We previously observed that peritumoral adipose tissue plays a role in lymph node involvement in esophageal adenocarcinoma (EAC) (4) and some reports suggest that adipose derived stem cells (ADSC) may have a role in the interplay between obesity and cancer. (5, 6) ADSC can differentiate into cancerassociated fibroblasts under the influence of specific tumorderived factors (7) and cumulative evidence supports the hypothesis that cancer-associated adipose tissue represents a key component in carcinogenesis. (8) On the basis of these reports, several studies investigated the relationship between the expression of specific genes in the tumor microenvironment and their potential association with chemotherapy.
CD34, a mesenchymal stem cell marker usually used to identify microvessel density in the tumor microenvironment, is reduced in breast cancer (9) and prostate cancer (10) after neoadjuvant treatment and is usually related to vascular endothelial growth factor (VEGF) expression, which negatively correlates with the response to neoadjuvant therapy in esophageal cancer tissue. (11) CD90, another mesenchymal stem cell marker implicated in the regulation of fibrosis, is expressed by ADSC and is upregulated in cancer-associated fibroblasts, and it has been shown to be related to recurrence in hepatocellular carcinoma (12) and to survival in neuroblastoma. (13) Nucleostemin (NSTM), a stemness marker expressed by cancer stem cells, is upregulated in recurrent esophageal carcinoma, (14) in advanced malignant phenotype of oral squamous cell carcinoma (SCC) (15) and in human breast cancer cells resistant to chemotherapy. (16) Octamer-binding transcription factor 4 (OCT-4), expressed in adult stem cells and mesenchymal adipose tissue, has been considered essential for anti-apoptotic behavior of chemoresistant cell lines. (17) Moreover, OCT-4 expression is increased in chemoresistant stem-like cells with low reactive oxygen species and in tumor treated with neoadjuvant therapy. (18) All these data suggest that specific cellular cross-talk may be involved in tumor biology such as invasiveness and/or recurrence. However, although the expression of CD34, CD90, NSTM and OCT-4 has been widely investigated in cancer cells, no data exist on their expression in the adipose tissue microenvironment of EAC.
Our hypotheses are that peritumoral adipose tissue plays a crucial role in tumor development through progressive involvement in neo-angiogenesis throughout the carcinogenesis process, and through a continuous cross-talk between cancer tissue and adipose stem cells surrounding EAC. Interaction between cancer cells and adipose cells may influence cancer behavior and its resistance to chemotherapy. Therefore, the aim of the present study was to investigate the cross-talk between cancer tissue and peritumoral adipose tissue and to correlate this to the response to neoadjuvant therapy in patients with EAC.
Materials and Methods
Study design. The first step of the present study aimed to assess angiogenesis in periesophageal adipose tissue during esophageal carcinogenesis. A surgical rat model of gastrointestinal reflux was chosen to reproduce the different steps of esophageal carcinogenesis. Procedures involving animals and their care were conducted according the Ethical Committee of Animal Experimentation of University of Padua (Comitato Etico di Ateneo sulla Sperimentazione Animale -CEASA).
In the second step, we aimed to analyze peritumoral adipose tissue in patients treated or not treated with neoadjuvant therapy, in order to assess the relationship between adipose tissue-specific gene expression and the response to neoadjuvant therapy. Adipose tissue from 60 consecutive patients with EAC and 20 with esophageal squamous cell carcinoma (SCC) who underwent esophagectomy at the Esophageal and Digestive Tract Surgical Unit of the Veneto Institute of Oncology (IOV-IRCSS) were collected and analyzed. This prospective study obtained the approval of the Ethical Committee of the Veneto Institute of Oncology (IOV-IRCSS). The study was carried out in accordance with the principles of the Helsinki Declaration and all potential patients were asked to give written consent to have their data (including age, sex, tumor location and size, treatment protocol, histology, TNM stage, and outcome) collected. Finally, in the third step, we aimed to study the possible cross-talk between cancer tissue and the peritumoral adipose tissue surrounding the EAC and its influence on the response to neoadjuvant therapy. Thus, we carried out several in vitro analyses of adipose tissue stem cells, using visceral adipose tissue of 18 patients who underwent abdominal surgery for benign conditions to isolate ADSC, then treated the cells with conditioned medium isolated from both tumoral and adipose tissue of patients affected by EAC.
Surgical procedure to induce esophageal cancer in animals. In this step of the study, 10 male Sprague Dawley rats (Charles River, Lecco, Italy) were consecutively submitted to a side-toside surgical esophagogastric-jejunal anastomosis. The animals were kept under standard laboratory conditions and acclimatized for a week before the procedure. Water and standard chow food were given ad libitum before surgery. Water was permitted 2 h after surgery, and rat chow was provided on the following day. Postoperatively, the animals were housed individually in a conventional cage. Five male non-operated rats of the same age were used as control animals.
The operation was carried out according to the microsurgical procedure previously described. (19) Briefly, a 1.5 cm side-toside surgical esophagogastric-jejunal anastomosis was created between the first jejunal loop and the gastroesophageal junction, approximately 3 cm distal to Treitz's ligament, with accurate mucosa-to-mucosa opposition, allowing jejunal and gastric contents to flow back into the esophagus. The surviving animals were killed at 28 AE 2 weeks after surgery.
Pathology and immunohistochemistry of animal specimens. Immediately after death, the thoracic and abdominal cavities were examined and the esophagus, stomach, and jejunum were excised en bloc. Gross specimens were fixed in 10% neutral-buffered formalin for 24 h. All specimens were cut serially (2-3-mm thick coronal sections). Tissue sections (4 lm thick) were obtained from paraffin blocks and stained with hematoxylin & eosin or with anti-CD34 (monoclonal rabbit EP373Y; Abcam, Cambridge, UK), aAnti-CD31 (mouse monoclonal cloneJc70A; DakoDenmark A/S, Glostrup, Denmark), or anti-VEGF (rabbit polyclonal to VEGFA; Abcam) and then counterstained with hematoxylin. Immunocomplexes were detected using the Dako Real Envision System Peroxidase/DAB (Dako, Glostrup, Denmark). CD34, CD31 and VEGF positive cells per mm 2 were counted in 10 different microscopic areas for each section by a single pathologist in a blinded way.
Preoperative staging and neoadjuvant therapy in patients.
Based on preoperative staging and according to the recommendations of the multidisciplinary team work-up, patients with tumors staged above T3N0 or any T N1 were considered suitable for neoadjuvant therapy. Patients were considered resectable when staged below T3N0 or, after the termination of neoadjuvant treatment, when there was no evidence of distant metastases or locally advanced tumor with gross periesophageal involvement at restaging.
Preoperative chemotherapy regimen for patients who were prescribed combined modality therapy consisted of 5-fluorouracil (5-FU) and a platinum agent (standard regimen for treatment was DDP 100 mg/m 2 on day 1, and 5-FU 1000 mg/m 2 per day in continuous infusion from day 1 to day 5 for 3-4 cycles). Chemotherapy was usually given concurrently with radiation therapy: radiation was usually given in daily fractions of 1.8 Gy for a total dose of 45-50 Gy. For carcinoma of the lower third esophagus, the field was extended to include both the perigastric and celiac nodes. This involved an initial phase using anteroposterior/posteroanterior fields with a total dose up to 30.6 Gy in 1.8 fractions. Patients prescribed chemotherapy only underwent two cycles of cisplatin in combination with 5-FU before surgery. After the second cycle of chemotherapy, the tumor was restaged and patients with stable or progressive disease at that point underwent surgery without further delay. A third cycle of chemotherapy was begun in those patients who responded to the first two cycles. In all cases, surgery was carried out 3-4 weeks after the last cycle of chemotherapy. (20) Surgical resection and tissue sample collection. Details concerning surgical techniques have been published elsewhere. (21) Briefly, esophagectomy was carried out using an Ivor Lewis procedure, by laparotomy or laparoscopy, and right thoracotomy for tumors of the midlower esophagus and the gastric cardia. During surgical procedures, two biopsies of visceral adipose tissue were collected for each patient from different fat depots. In particular, one sample from a periesophageal depot (2 cm close to cardia) and one sample from a distal omental depot (at least 15 cm from the esophagogastric junction). Thus, in patients with EAC, the periesophageal depot was close (within 2 cm) to the tumor site, whereas in patients with SCC, the periesophageal depot was at least 6-8 cm from the tumor site. One sample of tumoral tissue from the esophageal mucosa was also isolated from nine patients. Fresh specimens were rapidly divided and prepared for in vitro culture, or immediately frozen in liquid nitrogen, or fixed in formalin for subsequent analysis.
Immunohistochemistry of patient specimens. Formalin-fixed adipose tissue samples were paraffin-embedded and serial sections were immunostained with anti-human CD34 (clone QBEnd-10; DakoDenmark A/S), anti-human CD45 and antihuman CD31 (both from Abcam) according to the manufacturer's instructions. Double staining for CD34 and C/EBPa was done using an automated staining system (BOND-MAX; Leica Biosystems, Wetzlar, Germany). Heat-induced antigen retrieval was carried out using ER1 solution (pH6; Leica Biosystems) for 30 min. Anti-CD34 antibody (clone QBEnd-10; Dako) was incubated, followed by 15 min of AP-labeled polymer (Bond Polymer Refine Red detection system; (Leica Biosystems). Red substrate was incubated for 15 min. Anti-C/ EBPalpha (D56F10) (Cell Signaling Technology, Danvers, MA, USA) immunostaining was carried out subsequently using the Bond Polymer Refine Detection kit (Leica Biosystems). Staining was developed using 3,3 0 diaminobenzidine (DAB) chromogen (Leica) for 10 min. Slides were counterstained with hematoxylin, dehydrated, and coverslipped. Ten areas (1 mm 2 ) for each section were analyzed and all the parameters were measured by computer-assisted morphometric analysis (ImagePro Plus version 5).
ADSC isolation and treatment. Adipose-derived stem cells were isolated from omental adipose tissue of 15 patients undergoing abdominal surgery for non-neoplastic conditions. Briefly, freshly collected adipose tissue was collected from a distal omental adipose depot (peritoneal) and separated from major vessels and fibers, minced and digested with 1 mg/mL collagenase type II (Sigma-Aldrich, St Louis, MO, USA) in DMEM/F12 at 37°C for 1 h. Cell suspension containing stromal vascular fraction was centrifuged (350 g, 8 min), pelleted and resuspended in erythrocyte-lysing buffer, washed in DMEM/F12, filtered with a 100-lm cell strainer, centrifuged (350 g, 8 min), washed again in DMEM/F12 and seeded in DMEM/F12 supplemented with 10% FBS (0.7 9 10 6 cells/ well in 24-well plates). After 24 h for cell attachment, cells were washed twice in warm sterile PBS and medium was replaced by simple culture medium (control cells) or conditioned media from cultured tissue biopsies from EAC patients (CM-treated cells), collected as previously described.
(4) Leptin antagonist treatment was carried out by adding 0.7 ng/mL super human leptin antagonist (SHLA; Protein Laboratories Rehovot Ltd) to culture medium. After 48 h of treatment, cells were washed twice with warm PBS and harvested for subsequent analysis. For adipocyte differentiation, after 48 h of CM treatment, cells were washed twice in warm PBS and incubated with adipogenic medium: DMEM/F12 supplemented with 33 lM biotin, 17 lM pantothenate, 10 lg/mL human transferrin (Sigma-Aldrich), 66 lM insulin (Lilly Research, Indianapolis, IN, USA), 100 lM dexamethasone, 1 lM T 3 , 0.25 lM 3-isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich) and 10 lM rosiglitazone. Rosiglitazone and IBMX were removed after 3 days, and the medium was changed three times per week until complete differentiation was obtained (after 10 days). Preadipocytes maintained in DMEM/F12 alone were used as controls (undifferentiated cells).
Cytofluorimetric analysis. Surface expression of CD34, CD31 and CD45 cells was assessed by cytofluorimetric analysis. Briefly, 200 000 freshly isolated ADSC were washed twice in warm PBS, pelleted and stained with 10 lL of the following antibodies: anti-human CD34 PerCP-Cy TM 5.5 (clone 8G12), anti-human CD45 FITC (clone 2D1) and Phycoerythrin mouse anti-human CD31 (clone WM59) (all from BD Biosciences, Franklin Lakes, NJ, USA). Samples were washed in ice-cold FACS buffer (2% BSA in PBS), pelleted and resuspended in ice-cold FACS buffer. BD FACSCalibur TM flow cytometer (BD Biosciences) was used for acquisition and CellQuest software was used for analysis. Fluorescence of cells treated with fluorescent isotype monoclonal antibody was evaluated in each experiment to determine the level of background fluorescence of negative cells.
RNA isolation and real-time quantitative PCR. Total RNA was isolated from frozen visceral adipose tissues and ADSC using Rneasy Lipid Tissue Mini Kit and Rneasy Mini Kit (Qiagen, Hilden, Germany) respectively, treated with DNase (TURBODNase-free; Life Technologies, Carlsbad, CA, USA) and reverse transcribed using random primers (Promega, Madison, WI, USA) and M-MLV reverse transcriptase (Promega). mRNA levels were measured by real-time PCR (DNA Engine Opticon 2; Bio-Rad, Hercules, CA, USA) using SYBR Green PCR Master Mix (Life Technologies) and specific intron-spanning human primers, according to the manufacturer's instructions. Values were calculated as the mean of triplicate measurements and levels were normalized to hydroxymethylbilane synthase (HMBS) mRNA expression.
Statistical analysis. All statistical analyses were carried out using GraphPad Prism software version 6.0 (GraphPad Software, San Diego, CA, USA). Parametric one-way ANOVA and non-parametric Mann-Whitney U-test (or Kruskal-Wallis test when comparing more than two groups) were carried out to assess differences between continuous variables with Bonferroni correction for multiple comparison when appropriate. Results are expressed as mean AE SEM and in vitro experiments were carried out in triplicate. All tests were two-sided and a P-value <0.05 was considered significant.
Results
Angiogenesis in periesophageal adipose tissue of a rat model for EAC. Barrett's mucosa and, subsequently, a spontaneous form of EAC were obtained in the esophagus of operated rats, promoted by a surgically induced gastric reflux chronic exposure (Fig. 1a, H&E) . In order to evaluate angiogenesis in periesophageal adipose tissue depot of animals, we measured the immunohistochemical expression of CD34-, CD31-and VEGF-positive cells in non-operated rats (Normal), rats with Barrett's mucosa (Surgery-BM) and rats that had fully developed EAC (Surgery-EAC). We observed a significant increase in CD34-positive adipocytes in periesophageal adipose tissue of operated rats in comparison with non-operated control rats (Fig. 1a: CD34 ). In particular, CD34 was significantly more abundant in the peritumoral adipose tissue of rats that developed EAC compared to rats with simple Barrett's mucosa (OCT-4) mRNA expression was measured by means of qRT-PCR using HMBS as internal control. Parametric and non-parametric statistics were used. *P < 0.05; **P < 0.01 and ***P < 0.001. (Fig. 1b) . Similar results were obtained for CD31 (Fig. 1a : CD31) and VEGF (Fig. 1a: VEGF) expression, which significantly increased in peritumoral adipose tissue throughout cancer development (Fig. 1b) .
Peritumoral adipose tissue in patients not treated with neoadjuvant therapy. Mean age of patients was 62 (54.5-70) years for EAC and 64.5 (58.5-70.5) years for SCC patients. All adenocarcinomas were located in the esophagogastric junction and all SCC were located in the upper thoracic esophagus. Fourteen EAC patients and eight SCC patients underwent surgery alone, whereas 46 EAC patients and 12 SCC patients also underwent neoadjuvant therapy. Twenty-eight EAC patients and 17 SCC patients did not have lymph node metastases, whereas 32 EAC patients and three SCC patients had positive lymph node involvement. Additional clinical characteristics of patients and tumor staging data are summarized in Table S1 . We first measured immunohistochemical expression of CD34, CD45 and CD31 in sections of periesophageal (<2 cm from cardia) adipose tissue of EAC patients not treated with neoadjuvant therapy (EAC PT [peritumoral]; Fig. 1c) . As control tissues, we used a fat depot distant from the tumor: the omental (OM) adipose tissue of EAC patients (EAC OM) and the periesophageal (<2 cm from cardia) adipose tissue of SCC patients (SCC PE) who developed a tumor in the upper portion of the esophagus, distant from the cardia. Expression of CD34 and CD45 was increased in peritumoral adipose tissue of EAC patients (EAC PT), in comparison with both omental adipose tissue of EAC patients (EAC OM) and periesophageal adipose tissue of SCC patients (SCC PE). Also, CD31 expression showed a slight increase in EAC peritumoral adipose tissue, although no significant differences were detected among the three different groups (Fig. 1c) . CD34 and NSTM mRNA expression was increased in peritumoral adipose tissue of EAC patients, in comparison with both omental adipose tissue of EAC patients and periesophageal adipose tissue of SCC patients. Moreover, CD90 expression was increased in peritumoral adipose tissue of EAC patients compared to periesophageal adipose tissue of SCC patients (Fig. 1d ).
Peritumoral adipose tissue in patients treated with neoadjuvant therapy. We measured the expression of CD34, NSTM, CD90 and OCT-4 in peritumoral adipose tissue of EAC patients and we observed a significantly decreased mRNA expression of CD34, CD90 and NSTM in patients treated with neoadjuvant therapy, in comparison with patients who did not receive neoadjuvant treatment (Fig. 2a) . The lower expression of CD34 was also confirmed by immunohistochemical analysis (Fig. 2b) and adipocyte-specific expression of CD34 in peritumoral adipose tissue was confirmed by double staining for CD34 and the adipose-specific marker C/EBPa (22) (Fig. 2c) . In order to evaluate a possible relationship between the pathological response to radiochemotherapy and peritumoral adipose tissue gene expression, we measured mRNA levels of CD34, NSTM, CD90 and OCT-4 in peritumoral adipose tissue of EAC patients who had undergone neoadjuvant therapy. CD90 expression was decreased, whereas OCT-4 was increased in patients with poor response to treatment (Mandard Index from 3 to 5) in comparison with peritumoral adipose tissue isolated from patients with a better response to therapy (Mandard Index from 1 to 2) (Fig. 2d) . We investigated gene expression of VEGF in omental and peritumoral adipose tissue of EAC patients. VEGF mRNA levels were increased in peritumoral adipose tissue of patients with poor response to treatment (Mandard Index from 3 to 5) in comparison with peritumoral adipose tissue isolated from patients with a better response to therapy (Mandard Index from 1 to 2) (Fig. 2e) . Omental adipose tissue did not show significant differences in terms of VEGF mRNA expression in patients with poor response to treatment compared with patients with a better response to therapy; however, VEGF levels were significantly lower in comparison with peritumoral depot in patients who did not receive neoadjuvant treatment (Fig. 2e) . Circulating leptin and adiponectin were also measured, but there were no significant differences in their levels between patients with positive or negative lymph node involvement, different tumor sizes or different responses to neoadjuvant therapy (Fig. S1) . Moreover, adiponectin mRNA levels were measured in peritumoral and distal adipose tissue of EAC patients and we did not observe significant correlations with angiogenesis (CD31 and CD34 expression) or chemoresistance (Mandard Index) in EAC patients (Fig. S2) .
Effects of cancer-derived conditioned medium on ADSC gene expression. To investigate whether EAC could influence ADSC gene expression, we analyzed the effects of a cancerderived conditioned medium (CD-CM) collected from tumoral esophageal mucosa of patients affected by EAC on primary ADSC isolated from healthy visceral adipose tissue of patients undergoing abdominal surgery for benign diseases. Collection of ADSC from non-cancer patients allowed us to reproduce the effect of cancer-derived secreted factors on a healthy cell population to avoid misleading results from experiments on tumor-derived ADSC. After 48 h of treatment with CD-CM, we analyzed the expression of CD34, NSTM, CD90, OCT-4, a-SMA, E-cadherin, VEGF and VEGF-C and we observed that NSTM, a-SMA, VEGF and VEGF-C levels were increased, whereas E-cadherin levels were decreased in ADSC treated with CD-CM compared to untreated ADSC (Fig. 3a) .
Effects of peritumoral and distal adipose tissue conditioned medium on ADSC gene expression and adipocyte differentiation. In order to investigate the potential mechanism by which adipose tissue may influence ADSC expression and whether peritumoral adipose tissue is able to induce depot-specific effects on ADSC, we treated healthy visceral ADSC with adipose tissue conditioned medium (AT-CM) collected from peritumoral and distal adipose tissue biopsies. After 48 h of treatment with CM, the population of CD34+/CD45-/CD31-cells was significantly higher in cells treated with peritumoral adipose tissue CM in comparison with cells treated with omental adipose tissue CM or untreated control cells (Fig. 3b) . We then analyzed the expression of CD34, CD90, NSTM and OCT-4 from day zero and during a 10-day adipogenic differentiation of ADSC. mRNA expression of CD34 and NSTM at the end of the differentiation protocol remained higher in cells treated with peritumoral adipose tissue CM in comparison with cells treated with omental adipose tissue CM, or untreated control cells (Fig. 3c) . Similar results were observed in undifferentiated cells, which were maintained in culture without any adipogenic stimulus added to the medium and tended to maintain the mRNA expression of all the stemness genes during the differentiation process (Fig. 3c) .
Quantification of stemness capacity was carried out at the end of the adipogenic differentiation protocol in both an ex vivo cell fraction (passage 0, P0) and a P1 cell fraction (after one subculture passage). Oil Red O staining showed that, despite a general well-known loss of differentiation capacity in P1 cells compared to the ex vivo fraction, ADSC treated with peritumoral adipose tissue CM maintained a higher differentiation capacity after a P1 subculture, whereas cells treated with (Mandard 1-2) or a poor response to chemotherapy (Mandard 3-5). mRNA expression was measured by means of qRT-PCR using HMBS as internal control. Non-parametric statistics were used. *P < 0.05 and **P < 0.01. ) were used as negative controls. mRNA expression was measured by means of qRT-PCR using HMBS as internal control. Non-parametric statistics were used. *P < 0.05, **P < 0.01 and ***P < 0.001.
omental adipose tissue CM substantially decreased their adipogenetic potential (Fig. 3d) . Also, we measured the percentages of CD34+/CD45-/CD31-cells and the mRNA expression of CD34, NSTM, CD90 and OCT-4 in ADSC treated with peritumoral adipose tissue CM in the presence of a leptin antagonist (SHLA). Our results demonstrated that the leptin antagonist partially inhibited the effect of peritumoral adipose tissue CM treatment (Fig. 3e) .
Effects of peritumoral and distal AT-CM associated with neoadjuvant therapy and chemoresistance. CD34, NSTM, CD90 and OCT-4 expression was analyzed in ADSC treated with AT-CM. ADSC treated with AT-CM derived from omental adipose tissue showed dramatically lower mRNA levels compared to ADSC treated with AT-CM from peritumoral adipose samples and did not show any significant difference in mRNA expression between patients treated or not treated with neoadjuvant therapy (Fig. 4a) . In ADSC treated with peritumoral AT-CM, mRNA expression of CD34 and OCT-4 was significantly decreased in cells treated with AT-CM of patients who underwent neoadjuvant therapy compared to cells treated with AT-CM derived from untreated patients (Fig. 4a) .
Adipose-derived stem cells treated with AT-CM derived from omental adipose tissue samples did not show any significant difference in mRNA expression between patients with good or poor response to neoadjuvant therapy (Fig. 4b) . Interestingly, ADSC treated with AT-CM isolated from peritumoral adipose tissue of patients with bad response showed a significantly increased expression of NSTM and OCT-4 mRNA compared to cells treated with CM from patients with a good response (Fig. 4c) . In the same ADSC, we measured the mRNA expression of Leptin, Leptin receptor (ObR) and a-SMA and we observed that these genes were all upregulated in cells treated with peritumoral adipose tissue CM from patients with a bad response compared to CM derived from patients with a good response to neoadjuvant therapy (Fig. 4c) .
Finally, we measured ADSC gene expression during a 10-day adipogenic differentiation protocol, after a 48-h treatment with CM from peritumoral adipose of EAC patients. At the end of adipogenic differentiation, CD34 and VEGF mRNA levels were higher in ADSC treated with AT-CM of biopsies isolated from tissue of patients with a bad response compared to cells treated with AT-CM derived from patients with a good response to neoadjuvant therapy (Fig. 4d) .
Discussion
Several studies suggest that adipose tissue and stem cells play an important role in resistance to therapy (23) and tumor relapse. (24) (25) (26) The relentless growth of epithelial carcinomas, compounded with resistance to therapy, still represents a major clinical challenge that might be correlated with the involvement of other cell types.
In order to assess the role of adipose tissue vascularization in esophageal carcinogenesis, we investigated vessel distribution and angiogenesis expression in periesophageal adipose tissue of a surgical rat model where reflux induced by surgical esophagogastricjejunal anastomosis promoted a spontaneous form of EAC in Barrett's esophagus, as reported in a previous study. (27) These data could not have been observed in humans as the analysis of periesophageal tissue in healthy subjects and in patients with Barrett's esophagus would have implied an unnecessary invasive operation.
We measured the expression of CD34 and VEGF in peritumoral adipose tissue of rats and we observed a progressive increase in rats with Barrett's mucosa and rats that developed EAC in comparison with controls. Moreover, we verified in tissue sections that a component of this increase was adipocyte-derived, confirming a direct involvement of adipose cells in these alterations. These results suggest that peritumoral adipose tissue is enriched with factors able to stimulate and enhance the formation of new vessels and whose expression is increased during EAC development. In fact, we observed that the abundance of CD31-positive vessels in the peritumoral adipose tissue directly correlated with the progression of EAC development, from normal mucosa of non-operated rats, through an intermediate stage of Barrett's mucosa, to a fully developed EAC. As rats were killed at the same time, we assume that the difference in terms of vascularization could not be attributed to a different exposure to gastric reflux and to chronic inflammation; therefore, during carcinogenesis of EAC, peritumoral adipose tissue actively contributes to neovascularization, possibly favoring tumor progression. In order to evaluate a possible relationship between the pathological response to neoadjuvant therapy and the characteristics of peritumoral adipose tissue, we first characterized the expression profile of different fat depots in EAC patients not treated with neoadjuvant therapy in terms of angiogenesis, inflammation and stemness. We used adipose tissue of a depot distant from the tumor (omental in case of EAC or pericardial in case of SCC) as control tissue, given the impossibility of safely sampling a periesophageal specimen from healthy subjects. Immunohistochemical and gene expression analysis showed an increase of CD34, CD45 NSTM and CD90 in peritumoral adipose tissue of patients, in agreement with the results observed in other tumors. (28, 29) Moreover, we did not observe any significant correlation between clinicopathological data and circulating levels of leptin and adiponectin, further suggesting a local action of microenvironment-specific factors. Thus, we hypothesized that even in humans, EAC might be surrounded by a microenvironment that promotes adipose tissue vascularization, inflammation and fibrogenesis.
To verify whether these findings may represent a direct action of EAC on peritumoral adipose tissue, we first analyzed the effects of a CD-CM on primary ADSC isolated from healthy patients. With this experimental approach, we aimed to recreate the cross-talk between tumor-derived secreted factors and normal ADSC. In ADSC treated with CD-CM we observed an increase in the expression of genes involved in stemness (NSTM), epithelial-mesenchymal transition (EMT) (a-SMA and E-cadherin), neoangiogenesis (VEGF) and neolymphangiogenesis (VEGF-C), suggesting that EAC may exert a paracrine effect on peritumoral adipose stem cells. To further explore whether adipose tissue itself may affect the expression of ADSC, we treated adipose stem cells with AT-CM isolated from two different fat depots. Treatment of ADSC with peritumoral (but not distal) AT-CM led to an enrichment of the CD34+/CD45-/CD31-subpopulation, which represents the more adipose-specific expression profile, characterized by a major adipogenic potential as a result of the exclusion of pericytes (CD34-), endothelial (CD31+) and hematopoietic (CD45+) components, as shown in different studies (30, 31) and induced ADSC to maintain a higher expression of stemness genes during their differentiation towards mature adipocytes. These effects were reflected by the differentiation capacity of peritumoral AT-CM-treated ADSC observed after the first subculture passage and were partially inhibited by a leptin antagonist, indicating that leptin may be a potential player in this cross-talk, as already suggested by our previous study. (4) We also measured the expression of adiponectin in order to investigate a possible involvement of this adipokine in the observed effects, but we did not observe any significant correlation with angiogenesis or chemoresistance of patients. Therefore, these findings, associated with those obtained in distal (omental) adipose tissue, indicate that there is a paracrine effect of EAC on adipose stem cells that may promote vascularization and lymphangiogenesis, and a depotspecific effect of adipose tissue on the same cells that may increase their differentiation capacity and their expression of factors involved in cell stemness.
Decreased mRNA expression of CD34, CD90 and NSTM was detected in peritumoral tissue of patients who underwent neoadjuvant treatment and was partially reflected in the expression profile of ADSC treated with peritumoral CM of these patients. These results were not reflected in the omental depot of adipose tissue and suggest that neoadjuvant therapy can directly influence peritumoral adipocytes, decreasing the expression of key genes and, probably, inhibiting peritumoral vascularization and fibrogenesis. To further investigate this, we evaluated the potential relationship between the pathological response to neoadjuvant therapy and the expression profile of peritumoral adipose tissue. We observed that CD90 expression was decreased, whereas VEGF and OCT-4 were upregulated in peritumoral adipose tissue of patients who poorly responded to treatment. Moreover, in vitro, ADSC treated with peritumoral AT-CM obtained from these patients showed a significantly increased expression of NSTM, OCT-4, leptin, leptin receptor and a-SMA. Furthermore, CD34 and VEGF levels were also increased during their differentiation process in comparison with ADSC treated with CM of patients with a good response to treatment. These data suggest that an expression profile of adipose cells, characterized by an enhanced capacity to express factors involved in EMT (such as a-SMA) or in the stimulation of angiogenesis (such as VEGF), may be associated with the lack of response to neoadjuvant treatment in EAC patients. Interestingly, other aggressive tumors showing solid morphology with poor chemotherapy response demonstrated higher levels of these molecules. (32) (33) (34) These characteristics may contribute to create a permissive microenvironment that allows the tumor to be more resistant to the effects of chemotherapy, as we observed in patients with poor response. The periesophageal (within 2 cm from the gastric cardia) adipose tissue analyzed in this study must be considered a peritumoral microenvironment for adenocarcinoma located in the esophagogastric junction and not for SCC that was located in the upper portion of esophagus. In fact, the correlation between adipose tissue-specific markers expression and angiogenesis or chemoresistance that we observed in patients affected by EAC were not significant in patients affected by SCC.
In conclusion, our results indicate that adipose tissue surrounding EAC is rich in factors promoting tissue stemness, inflammation and neo-angiogenesis, as we observed in both the animal model and in patients, and these processes may be induced by tumor through paracrine signaling (Fig. 5) . Furthermore, neoadjuvant therapy can directly influence peritumoral adipocytes, which, in turn, are able to induce the expression of key genes in adipose stem cells and enhance their capacity to express factors involved in extracellular matrix remodeling and neo-angiogenesis. These effects were significantly increased in chemoresistant patients with EAC, reinforcing the concept that depot-specific adipose tissue characteristics may represent a potential prognostic index after surgery for EAC patients undergoing neoadjuvant therapy.
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